Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Subrata Ghosh; Lianne S Gensler; Zijiang Yang; Chris Gasink; Soumya D Chakravarty; Kamyar Farahi; Paraneedharan Ramachandran; Elyssa Ott; Bruce E Strober

doi:10.1007/s40264-019-00816-3

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Subrata Ghosh, Lianne S Gensler, Zijiang Yang, Chris Gasink, Soumya D Chakravarty, Kamyar Farahi, Paraneedharan Ramachandran, Elyssa Ott, Bruce E Strober

Immunology and Immunotherapy

Research output: Contribution to journal › Comment/debate › peer-review

4 Citations (Scopus)

Abstract

In the original publication of this article, the following correction should be noted in Table 5.

The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

Original language	English
Pages (from-to)	809
Number of pages	1
Journal	Drug Safety
Volume	42
Issue number	6
Early online date	22 Apr 2019
DOIs	https://doi.org/10.1007/s40264-019-00816-3
Publication status	Published - 4 Jun 2019

Access to Document

10.1007/s40264-019-00816-3Licence: None: All rights reserved

4 Citations
1 Article

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: an integrated analysis of Phase II/III Clinical Development Programs
Ghosh, S., Gensler, L. S., Yang, Z., Gasink, C., Chakravarty, S. D., Farahi, K., Ramachandran, P., Ott, E. & Strober, B. E., Jun 2019, In: Drug Safety. 42, 6, p. 751-768 18 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
34 Citations (Scopus)

211 Downloads (Pure)

Cite this

@article{3c674bba7d9646de98598092a5c20dd8,

title = "Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs",

abstract = "In the original publication of this article, the following correction should be noted in Table 5.The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.",

author = "Subrata Ghosh and Gensler, {Lianne S} and Zijiang Yang and Chris Gasink and Chakravarty, {Soumya D} and Kamyar Farahi and Paraneedharan Ramachandran and Elyssa Ott and Strober, {Bruce E}",

year = "2019",

month = jun,

day = "4",

doi = "10.1007/s40264-019-00816-3",

language = "English",

volume = "42",

pages = "809",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Correction to

T2 - Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

AU - Ghosh, Subrata

AU - Gensler, Lianne S

AU - Yang, Zijiang

AU - Gasink, Chris

AU - Chakravarty, Soumya D

AU - Farahi, Kamyar

AU - Ramachandran, Paraneedharan

AU - Ott, Elyssa

AU - Strober, Bruce E

PY - 2019/6/4

Y1 - 2019/6/4

N2 - In the original publication of this article, the following correction should be noted in Table 5.The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

AB - In the original publication of this article, the following correction should be noted in Table 5.The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

UR - http://www.scopus.com/inward/record.url?scp=85064702543&partnerID=8YFLogxK

U2 - 10.1007/s40264-019-00816-3

DO - 10.1007/s40264-019-00816-3

M3 - Comment/debate

C2 - 31012051

SN - 0114-5916

VL - 42

SP - 809

JO - Drug Safety

JF - Drug Safety

IS - 6

ER -

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Abstract

Access to Document

Fingerprint

Research output

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: an integrated analysis of Phase II/III Clinical Development Programs

Cite this